HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis

Summary.  Liver steatosis is a main histopathological feature of Hepatitis C (HCV) infection because of genotype 3. Steatosis and/or mechanisms underlying steatogenesis can contribute to hepatocarcinogenesis. The aim of this retrospective study was to assess the impact of infection with HCV genotype 3 on hepatocellular carcinoma (HCC) occurrence in patients with ongoing HCV cirrhosis. Three hundred and fifty‐three consecutive patients (193 men, mean age 58 ± 13 years), with histologically proven HCV cirrhosis and persistent viral replication prospectively followed and screened for HCC between 1994 and 2007. Log‐rank test and Cox model were used to compare the actuarial incidence of HCC between genotype subgroups. The patients infected with a genotype 3 (n = 25) as compared with those infected with other genotypes (n = 328) had a lower prothrombin activity [78 (interquartile range 60–85) vs 84 (71–195) %, P = 0.03] and higher rate of alcohol abuse (48%vs 29%, P = 0.046). During a median follow‐up of 5.54 years [2.9–8.6], 11/25 patients (44%) and 87/328 patients (26%) with a genotype 3 and non‐3 genotype, respectively, develop a HCC. HCC incidences were significantly different among the genotype subgroups (P = 0.001). The 5‐year occurrence rate of HCC was 34% (95% CI, 1.3–6.3) and 17% (95% CI, 5.7–9.2) in genotype 3 and non‐3 genotype groups, respectively (P = 0.002). In multivariate analysis, infection with a genotype 3 was independently associated with an increased risk of HCC occurrence [hazard ratio 3.54 (95% CI, 1.84–6.81), P = 0.0002], even after adjustment for prothrombin activity and alcohol abuse [3.58 (1.80–7.13); P = 0.003]. For patients with HCV cirrhosis and ongoing infection, infection with genotype 3 is independently associated with an increased risk of HCC development.

[1]  L. Babiuk,et al.  Hepatitis C virus genotype-3a core protein enhances sterol regulatory element-binding protein-1 activity through the phosphoinositide 3-kinase-Akt-2 pathway. , 2010, The Journal of general virology.

[2]  Pierre Bedossa,et al.  Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. , 2010, Journal of hepatology.

[3]  B. McMahon,et al.  Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection. , 2010, Gastroenterology.

[4]  P. Francioli,et al.  Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. , 2009, Journal of hepatology.

[5]  Soo-Ho Choi,et al.  Non‐structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice , 2009, The Journal of pathology.

[6]  William M. Lee,et al.  Evolution of hepatic steatosis in patients with advanced hepatitis C: Results from the hepatitis C antiviral long‐term treatment against cirrhosis (HALT‐C) trial , 2009, Hepatology.

[7]  M. Mondelli,et al.  Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. , 2009, Journal of hepatology.

[8]  Y. Shin,et al.  Liver X receptor mediates hepatitis B virus X protein–induced lipogenesis in hepatitis B virus–associated hepatocellular carcinoma , 2009, Hepatology.

[9]  V. Paradis,et al.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis , 2009, Hepatology.

[10]  Chien-Hua Chen,et al.  Clinical significance of elevated alpha-fetoprotein (AFP) in chronic hepatitis C without hepatocellular carcinoma. , 2008, Hepato-gastroenterology.

[11]  J. Pawlotsky,et al.  Morphological changes in intracellular lipid droplets induced by different hepatitis C virus genotype core sequences and relationship with steatosis , 2008, Hepatology.

[12]  M. Manns,et al.  Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus , 2008, Hepatology.

[13]  F. Roudot-thoraval,et al.  Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. , 2008, Gastroenterology.

[14]  R. Jhaveri,et al.  Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. , 2008, The Journal of infectious diseases.

[15]  J. Pekow,et al.  Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C‐related cirrhosis , 2007, Cancer.

[16]  K. Koike Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways , 2007, Journal of gastroenterology and hepatology.

[17]  L. Babiuk,et al.  Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. , 2007, Journal of hepatology.

[18]  A. Mangia,et al.  Sustained virological response to interferon‐α is associated with improved outcome in HCV‐related cirrhosis: A retrospective study , 2007, Hepatology.

[19]  C. Datz,et al.  Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. , 2006, Gastroenterology.

[20]  P. Couzigou,et al.  Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study , 2005, Journal of viral hepatitis.

[21]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[22]  J. Pawlotsky,et al.  Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis , 2004, Gut.

[23]  K. Eguchi,et al.  Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection , 2003, Cancer.

[24]  M. Honda,et al.  Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. , 2002, Gastroenterology.

[25]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[26]  V. P. Chacko,et al.  Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? , 2001, Cancer research.

[27]  M. Gambardella,et al.  Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity , 2001, Hepatology.

[28]  K. Koike,et al.  Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. , 2001, Cancer research.

[29]  K. Abid,et al.  Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. , 2000, Journal of hepatology.

[30]  S. Chevret,et al.  Hepatocellular carcinoma without cirrhosis in the West: epidemiological factors and histopathology of the non-tumorous liver. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. , 1999, Journal of hepatology.

[31]  Yoshiharu Matsuura,et al.  The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice , 1998, Nature Medicine.

[32]  V. Paradis,et al.  In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. , 1997, Journal of clinical pathology.